Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists
Pigs: 2.5 - 10 ml
You are building them
All participating study subjects were informed about the design and aim of this study, and written consent was obtained
Shed Best for Dosing Format Flexibility OVERALL SCORE Good Based on our comprehensive hands-on evaluation Payments HSA / FSA eligible
Diabetes Care 25:13981404 Fonseca V, Baron M, Shao Q, Dejager S (2008) Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
US$ 23.32
US$ 27.67
US$ 23.62
US$ 21.32
